Loading…
Evi Labs LLC, a drug manufacturer in Medley, Florida, failed to comply with Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, rendering their OTC topical drug products adulterated. During a January 2025 inspection, the FDA identified that the company released batches of aluminum chlorohydrate-containing antiperspirant products without adequate strength and identity testing prior to distribution, in violation of 21 CFR 211.165(a). Test results for released lots, including Zermat Kiwi Perfumado, showed aluminum chlorohydrate concentrations that significantly exceeded labeled amounts and failed to meet established specifications. The company's response to the FDA's Form 483 was deemed inadequate due to lack of supporting documentation and insufficient evidence of corrective actions.